SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Midnight is a privacy-first blockchain that blends public verifiability with confidential data handling. You can use Midnight's selective disclosure and ZK proofs to build apps.

Midnight

Midnight ($NIGHT) is generating significant community conversation as traders weigh the platform's focus on privacy-enhancing ZK proofs against concerns regarding its decentralization and high-profile partnerships. While some supporters highlight its potential within the Cardano ecosystem and its recent network milestones, others are actively debating its valuation, the impact of token airdrops on market stability, and ongoing legal scrutiny involving the project's early NFT initiatives.

Global X Funds - Global X Defense Tech ETF

Global X Defense Tech ETF

The Global X Defense Tech ETF (SHLD) is trending as investors capitalize on surging global military spending and geopolitical instability, with the community highlighting its strategic exposure to both U.S. giants and international defense leaders. Traders are closely monitoring the ETF's resilience and its concentrated positions in high-growth AI and defense-tech names as a play on long-term sector tailwinds.

Nokia Oyj engages in the provision of network infrastructure, technology, and software services. It operates through the following segments: Mobile Networks, Network Infrastructure, Cloud and Network Services, and Nokia Technologies. The Mobile Networks segment offers technologies for Radio Access Networks (RAN) as well as Microwave Radio Links (MWR) for transport networks. The Network Infrastructure serves communication service providers, enterprises, webscales and public sector customers. The Cloud and Network Services segment builds around software and the cloud and is focused on driving leadership in cloud-native software and as-a-service delivery models, as demand for critical networks accelerates; and with strong market positions in communications software, private wireless networks, and cognitive (or intelligent) services. The Nokia Technologies segment, building on decades of innovation and R&D leadership in technologies used in virtually all mobile devices used today, is expanding the Nokia patent licensing business, reintroducing the Nokia brand to smartphones through brand licensing, and establishing a technology licensing business. The company was founded by Fredrik Idestam in 1865 and is headquartered in Espoo, Finland.

Nokia Corp - ADR

Nokia Corp

Nokia is trending as investors digest a mix of financial results and strategic positioning, with the community closely tracking the company's deepening integration into AI infrastructure and optical networking. While short-term volatility and mixed analyst outlooks drive debate, long-term investors are highlighting Nokia's role in next-generation connectivity as a key tailwind for the stock.

The mission of the Worldcoin project is to build the world’s largest identity and financial network as a public utility, giving ownership to everyone. A key component of the Worldcoin project is the development of the foundational infrastructure that will be important for a world where AI plays an increasingly large role.  The Worldcoin system revolves around World ID, a privacy-preserving global identity network. World ID enables users to verify their humanness online while maintaining their privacy through zero-knowledge proofs.  Using World ID, individuals will be able to prove that they are a real, unique human to any platform that integrates with the protocol, including to web3 systems, social networking sites, and governmental programs. This will enable fair airdrops or token/NFT sales, provide protection against bots/sybil attacks on social media, and enable the fairer distribution of limited governmental resources. Furthermore, World ID can also enable global democratic processes and novel forms of governance (e.g., via quadratic voting), and it may eventually show a path to AI-funded UBI. The Worldcoin token (WLD), alongside World ID, will let users participate in governing the Worldcoin protocol.   To engage with the Worldcoin protocol, individuals must first download a first wallet app that supports the creation of a World ID. Users visit a physical imaging device called the Orb to get their World ID Orb-verified. Orbs are operated by a network of independent local businesses called Orb Operators. The Orb uses multispectral sensors to verify humanness and uniqueness to issue an Orb-verified World ID, with all images being promptly deleted on-device per default (absent explicit consent to Data Custody). All Orb-verified World IDs holders are entitled to claim recurring grants of free WLD tokens, subject to certain availability restrictions. The WLD token is designed as a utility token with governance properties.

Worldcoin

Worldcoin is experiencing significant volatility as the community remains sharply divided, fueled by intense speculation regarding its integration with OpenAI and ongoing institutional accumulation by players like Eightco Holdings. While some investors view the biometric proof-of-personhood technology as a necessary pillar for the AI-driven internet, others are heavily criticizing its tokenomics and recent price performance, creating a highly polarized atmosphere ahead of upcoming roadmap milestones.

Harrow, Inc. engages in the development, production, and sale of innovative medications. It operates through the following segments: Pharmaceutical Compounding and Pharmaceutical Drug Development. The Pharmaceutical Compounding segment focuses on the operations of the ImprimisRx business. The company was founded by Mark L. Baum and Robert J. Kammer on January 11, 2006 and is headquartered in Nashville, TN.

Harrow Inc

Harrow Health Inc

Harrow Health is trending as investors focus on a pivotal period of growth, driven by expectations of a strong Vevye sales ramp following its move to preferred formulary status at CVS. Community discussions highlight high conviction in the stock's long-term potential, with many focusing on the company's expanding sales force and upcoming product launches as key catalysts for a significant revaluation in the coming quarters.

UP Fintech Holding Ltd. is an online brokerage firm that focuses on global investors. It provides an online trading platform that enables investors to trade in equities and other financial instruments on multiple exchanges around the world. The firm offers products and services, as well as a user experience to customers through its mobile first strategy. The company was founded by Tian Hua Wu in June 2014 and is headquartered in Singapore.

UP Fintech Holding Ltd - ADR

TIGR is currently trending as investors debate whether a potential diplomatic meeting between U.S. and Chinese leadership will stabilize the outlook for Chinese ADRs and trigger a rally in the stock. The community is actively discussing the stock's strong fundamental growth against the backdrop of broader market volatility, with many pointing to its shift toward non-mainland clients as a key point of divergence from its current market valuation.

Starbucks Corp. engages in the production, marketing, and retailing of specialty coffee. It operates through the following segments: North America, International, and Channel Development. The North America segment focuses on the United States and Canada. The International segment is involved in China, Japan, Asia Pacific, Europe, Middle East, Africa, Latin America, and Caribbean. The Channel Development segment includes roasted whole bean and ground coffees, Seattle’s Best Coffee, and Teavana-branded single-serve products. The company was founded by Jerry Baldwin and Howard D. Schultz on November 4, 1985, and is headquartered in Seattle, WA.

Starbucks Corp.

Starbucks Corp

Starbucks is facing significant volatility as investors debate the efficacy of its turnaround strategy amid store closures, labor cost pressures, and stiff competition from agile rivals like Luckin Coffee. While the community remains divided over management's execution and high valuation, recent analyst activity and leadership changes have intensified focus on whether the brand can successfully pivot to restore sustained profitability.

Energy Transfer LP engages in natural gas pipeline transportation and transmission services. It operates through the following segments: Intrastate Transportation and Storage, Interstate Transportation and Storage, Midstream, NGL and Refined Products Transportation and Services, Crude Oil Transportation and Services, Investment in Sunoco LP, Investment in USAC, and All Other. The Intrastate Transportation and Storage segment owns and operates natural gas transportation pipelines. The Interstate Transportation and Storage segment includes transportation pipelines, storage facilities, and gathering systems and delivery of natural gas to industrial end-users and other pipelines. The Midstream segment consists of natural gas gathering, compression, treating, processing, storage, and transportation. The NGL and Refined Products Transportation segment engages in the operations transport, store and execute acquisition, and marketing activities utilizing a complementary network of pipelines, storage and blending facilities, and strategic off-take locations that provide access to multiple NGL markets. The Crude Oil Transportation and Services segment provides transportation, terminalling, acquisition, and marketing services to crude oil markets. The Investment in Sunoco LP segment refers to the distribution of motor fuels to independent dealers, distributors, and other commercial customers and the distribution of motor fuels to end-user customers at retail sites. The Investment in USAC segment offers compression services to its customers in connection with infrastructure applications including both allowing for the processing and transportation of natural gas through the domestic pipeline system and enhancing crude oil production through artificial lift processes. The company was founded by Kelcy L. Warren in 1996 and is headquartered in Dallas, TX.

Energy Transfer LP - Unit

Energy Transfer LP Unit

Energy Transfer is trending as investors capitalize on increased natural gas demand driven by severe winter weather, boosting production volumes and short-term earnings expectations. The community is actively discussing the stock's role as a dividend-heavy play in the energy infrastructure sector, with many traders focused on breakout potential toward 20 dollars ahead of upcoming earnings and potential project catalysts.

Transocean Ltd. engages in the provision of offshore contract drilling services for oil and gas wells. It also owns and operates offshore drilling fleets such as ultra-deepwater, harsh environment, deepwater, and midwater rigs. The company was founded in 1953 and is headquartered in Steinhausen, Switzerland.

Transocean Ltd

Transocean is trending as investors digest a major merger agreement with Valaris alongside a positive earnings report that highlighted significant debt reduction and record fleet uptime. The community remains focused on the company's long-term offshore drilling turnaround, with many traders actively discussing potential price targets and the impact of these strategic shifts on future valuation.

Grayscale Investments LLC - Grayscale Bitcoin Trust

Grayscale Bitcoin Trust

The Grayscale Bitcoin Trust (GBTC) is currently a focal point of intense debate as investors weigh concerns over elevated management fees against its role as a proxy for broader Bitcoin price action. Market participants are actively scrutinizing the impact of institutional outflows and macroeconomic headwinds, while long-term bulls remain focused on the potential for institutional accumulation and BTC price recovery.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Recursion Pharmaceuticals (RXRX) Down 16.5% Since Last Earnings Report: Can It Rebound?

Recursion Pharmaceuticals (RXRX) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

WVE Posts Interim Data From Phase I Study on WVE-007, Stock Tanks

Wave Life Sciences stock plunges after interim phase I data for WVE-007 showed modest fat reduction at higher dose, despite some sustained benefits.

VKTX Finishes Enrollment in Second Late-Stage Study on Obesity Drug

Viking Therapeutics climbs after it completes enrollment in the second phase III obesity study for VK2735 and advances its bid in a fast-growing, competitive weight-loss market.

<ul class="summary-bullets"><li>Earlier on Thursday, Viking announced competition for patient enrollment in its late-stage clinical trial of subcutaneous VK2735.&nbsp;</li><li>Viking is now looking forward to advancing the oral version of its experimental obesity drug into late-stage study in the third-quarter (Q3) of 2026.</li><li>Viking CEO Brian Lian said earlier this month that the company will have four late-stage trials by the end of 2026.</li></ul>Shares of Viking Therapeutics Inc. (VKTX) closed 3% higher on Thursday amid speculation for a buyout, and an eventual approval from the U.S. Food and Drug Administration for its experimental obesity drug dubbed the “Ozempic killer.”A Stocktwits user recommended holding the stock, opining that it would remain “slow and steady” until FDA approval.<stembedurl>https://stocktwits.com/GREENCANDLELOVER/message/648672982</stembedurl>Another speculated a “big buyout" for the company.<stembedurl>https://www.stocktwits.com/timfris/message/648671668</stembedurl>Another user highlighted that the company’s obesity asset can dethrone Eli Lilly and Co.’s (LLY) supremacy in the obesity drug segment.<stembedurl>https://www.stocktwits.com/TrustButVerifi/message/648663298</stembedurl>Yet another user called the company’s obesity drug the “Ozempic killer.”<stembedurl>https://www.stocktwits.com/MetricWhale/message/648678023</stembedurl>Overall, retail sentiment around the stock improved from ‘bearish’ to ‘neutral’ territory over the past 24 hours, while message volume rose from ‘low’ to 'normal' levels.<h2 class="st-heading-2">Viking Completes Trial Enrollment</h2>Earlier on Thursday, Viking announced competition for patient enrollment in its late-stage clinical trial of subcutaneous VK2735, the company's experimental drug for weight loss. The trial enrolled about 1,000 patients with type 2 diabetes and who have obesity or who are overweight, the company said. The primary endpoint of the study is the percent change in body weight from baseline after 78 weeks of treatment for participants receiving VK2735 as compared to placebo. In a mid-stage trial, patients achieved up to 14.7% mean weight loss in 13 weeks on the drug.The dual agonist VK2735 is being developed in both oral and subcutaneous formulations. Viking is now looking forward to advancing the oral version of its experimental obesity drug into late-stage study in the third-quarter (Q3) of 2026.<h2 class="st-heading-2">Company Stays Bullish On Pipeline</h2>Viking CEO Brian Lian said earlier this month that the company will have four late-stage trials by the end of 2026.“2025 was a big year for us. 2026 is gonna be a big year as well,” Lian said at the Leerink Global Healthcare Conference.The CEO also expressed optimism that weight loss for the subcutaneous VK2735 trials will probably be a “little better than a GLP-1 monoagonist” though he couldn't predict its impact in comparison to other "polyagonists." While Novo Nordisk’s popular weight loss drug Wegovy is a single-agonist drug, Eli Lilly and Company’s Zepbound is a dual agonist.Viking is also looking to file an application to start trials for a novel amylin agonist this quarter, as it seeks to expand its obesity portfolio. Amylin agonists are a class of medication that mimic the hormone amylin, which is co-secreted with insulin by pancreatic -cells to manage glucose levels and appetite.<a href="https://stocktwits.com/symbol/VKTX">VKTX stock</a> has gained more than 30% over the past 12 months.Read More: <a href="https://stocktwits.com/news-articles/markets/equity/elon-musk-teases-three-row-tesla-suv-but-fails-to-ease-delivery-growth-fears/cZ3sEBvRIlE">Elon Musk Teases Three-Row Tesla SUV But Fails To Ease Delivery Growth Fears</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

In this photo illustration, a smartphone displays the logo of Viking Therapeutics, Inc., in front of a screen showing the company's latest stock market chart on July 19, 2025 in Chongqing, China. (Photo illustration by Cheng Xin/Getty Images)

VKTX Stock Jumps As Retail Traders Pile Into Obesity Pipeline Bets

A Stocktwits user recommended holding the stock, opining that the stock be “slow and steady” until FDA approval for the company’s experimental obesity drug VK2735. 

Equity

A Stocktwits user recommended holding the stock, opining that the stock be “slow and steady” until FDA approval for the company’s experimental obesity drug VK2735. 


Viking Therapeutics (NASDAQ:VKTX) Now Covered by Wolfe Research

Wolfe Research assumed coverage on shares of Viking Therapeutics in a report on Thursday. They set a "peer perform" rating for the company...

<ul class="summary-bullets"><li>Viking is developing VK2735 in both oral and subcutaneous formulations for the potential treatment of metabolic disorders such as obesity.</li><li>The company stated that the primary endpoint of the Phase 3 VANQUISH-2 study is the percentage change in body weight from baseline for participants receiving VK2735.</li><li>The company stated it expects to complete the VANQUISH studies in 2027.</li></ul>Viking Therapeutics Inc. (VKTX) on Thursday announced that it has completed enrollment in the Phase 3 trial of its obesity drug, VK2735, which is in the race to compete in the GLP-1 obesity drug market, dominated by Novo Nordisk's Ozempic and Wegovy.The company said that the Phase 3 VANQUISH-2 study will assess the efficacy and safety of VK2735 administered by subcutaneous injection once weekly for 78 weeks.Viking is developing VK2735 in both oral and subcutaneous formulations for the potential treatment of metabolic disorders such as obesity.<a href="https://stocktwits.com/symbol/VKTX">Viking Therapeutics shares</a> were up nearly 2% in Thursday’s opening trade. Retail sentiment on Stocktwits around the company trended in the ‘bearish’ territory.<h2 class="st-heading-2">What Are The Primary And Secondary Endpoints?</h2>Viking Therapeutics stated that the primary endpoint of the Phase 3 VANQUISH-2 study is the percentage change in body weight from baseline for participants receiving VK2735, compared to patients on placebo after 78 weeks of treatment.The secondary and exploratory endpoints include an evaluation of several efficacy and safety measures. This includes the percentage of patients who achieve 5%, 10%, 15% and 20% or more body weight reduction during the trial.“As with the VANQUISH-1 study, we are happy to see a study of this size enroll quickly, which we believe speaks to the enthusiasm for new obesity treatments beyond those currently available,” said Viking CEO Brian Lian.The company stated it expects to complete the VANQUISH studies in 2027.<h2 class="st-heading-2">Phase 3 Trial Update</h2>Viking also announced an update regarding its Phase 3 VANQUISH-1 study of subcutaneous VK2735 in patients who have obesity or are overweight.The company also stated that it is evaluating VK2735 in a Phase 1 study evaluating a range of potential maintenance dosing regimens. Results from the maintenance study are expected in the third quarter (Q3) of 2026.<a href="https://stocktwits.com/symbol/VKTX">VKTX stock</a> is down 6% year-to-date, but up 19% over the past 12 months. The S&amp;P Biotech ETF (XBI) is up 42% over the past 12 months, while the Vanguard Small-Cap Growth Index Fund ETF (VBK) is up 18%.Also See:&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/trump-iran-begging-for-deal-warns-get-serious-on-talks-dow-futures-fall/cZ3ru8hRIjM">Trump Says Iran ‘Begging’ For Deal, Warns Them To 'Get Serious’ On Talks — Dow Futures Fall More Than 300 Points</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

In this photo illustration, a person holds a smartphone displaying the logo of Viking Therapeutics on July 19, 2025. (Photo illustration by Cheng Xin/Getty Images)

Viking Therapeutics Moves Closer To Challenging Ozempic With Phase 3 Trial Progress

The company said that the Phase 3 VANQUISH-2 study will assess the efficacy and safety of VK2735 administered by subcutaneous injection once weekly for 78 weeks.

Viking Therapeutics Announces Completion of Enrollment in Phase 3 VANQUISH-2 Trial of VK2735

Viking Therapeutics Announces Completion of Enrollment in Phase 3 VANQUISH-2 Trial of VK2735 Viking Therapeutics Announces Completion of Enrollment in Phase 3 VANQUISH-2 Trial of VK2735 PR Newswire...

Why Viking Therapeutics, Inc. (VKTX) Dipped More Than Broader Market Today

In the closing of the recent trading day, Viking Therapeutics, Inc. (VKTX) stood at $32.17, denoting a -1.17% move from the preceding trading day.

Why Viking Therapeutics Stock Could Take Off Later This Year

Key PointsViking's GLP-1 drug, VK2735, is currently in the midst of multiple clinical trials...

HC Wainwright Reiterates "Buy" Rating for Viking Therapeutics (NASDAQ:VKTX)

HC Wainwright restated a "buy" rating and issued a $102.00 target price on shares of Viking Therapeutics in a report on Monday...

Viking Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which engages in the development of therapies for metabolic and endocrine disorders. The company was founded by Brian Lian and Michael A. Dinerman on September 24, 2012 and is headquartered in San Diego, CA.

Viking Therapeutics Inc

Peloswing

JFDI

ACInvestorBlog

GPaisa

A pillar of the Stocktwits ecosystem. This award recognizes the member who fosters connection, shares invaluable insights, and elevates the daily discussion to empower their fellow traders, on-platform.

Current Price	$32.52
Prev Close	$34.25
Open	$33.99
Dividend Yield	0.00%
50-Day Moving Average	$32.11
Beta	1.59
Avg. Volume	3.22M
PE Ratio	-10.22

52-Week High	$43.15
52-Week Low	$18.92
Market Capitalization	$3.76B
EPS (Annual)	-$3.19
Price to Book	5.84
Revenue Per Employee	$0.00

VKTX
Viking Therapeutics Inc

Feed

News

Sentiment

Earnings

Fundamentals

Info

Latest VKTX News

VKTXViking Therapeutics Inc